AbbVie drops two early-stage ADCs, including Pfizer-partnered oncology program
24 Aug 2023
ADC
AbbVie removed two early-stage antibody-drug conjugates from its pipeline, per a Wednesday update to its pipeline webpage.
ADCs have made a splash in the oncology R&D field in recent years, with AstraZeneca and Daiichi Sankyo’s Enhertu changing the landscape for HER2 breast cancer and Pfizer willing to dole out $43 billion to buy Seagen and its pipeline of cancer medicines.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.